Blueberries Medical Corp. is engaged in the production and distribution of psychoactive and non-psychoactive cannabis by-products. The company is headquartered in Toronto, Ontario. The company went IPO on 2014-04-09. The firm is fully licensed for the cultivation, production, domestic distribution, and international export of cannabidiol (CBD) and tetrahydrocannabinol (THC)-based medical cannabis in Colombia. The firm is focusing on cultivating, processing, and supplying medicinal-grade Cannabis oil extracts, medical flowers, and related products. Additionally, the Company distributes functional supplements, wellness products, and natural ingredients. The Company’s subsidiaries include Blueberries Research Corporation (BRC) and Blueberries SAS (BBSAS). BBSAS is a licensed producer and distributor of medicinal Cannabis and Cannabis-derived products in Colombia.
Leveraging in-depth analyst evaluations, we have synthesized key insights from expert assessments to present a positive outlook for BBRRF. Analysts highlight solid fundamentals and favorable market sentiment, suggesting upside potential in the near term. Based on this thorough expert analysis, we maintain an optimistic view of this stock. Our conclusion: BBRRF is a Buy candidate.
BBRRF stock price ended at $0.01 on 星期一, after rising 0.00%
On the latest trading day Jan 26, 2026, the stock price of BBRRF rose by 0.00%, climbing from $0.01 to $0.01. During the session, the stock saw a volatility of 0.00%, with prices oscillating between a daily low of $0.01 and a high of $0.01. Notably, trading volume dropped by 38.4K shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 46.9K shares were traded, equating to a market value of approximately $4.9M.